Explore News By Topic
Breast Cancer Research Foundation and Prostate Cancer Foundation Announce Their Commitment to Support the Blood Profiling Atlas in Cancer
In alignment with VP Biden’s Cancer Moonshot initiative, the Blood PAC formed in October 2016 to support progress towards patient benefit through research.
Prostate cancer is one of the most heritable forms of cancer. Hereditary mutations in “DNA repair” genes – BRCA1, BRCA2, and others – which are best known for their association with breast and ovarian cancer predisposition, are now known to be associated with advanced prostate cancer. In fact, ~12% of.
The Prostate Cancer Foundation’s 2016 Coffey-Holden Prostate Cancer Academy Meeting Accelerates Advances In The Understanding And Treatment Of Metastatic Prostate Cancer
The Prostate Cancer Foundation (PCF) has a legacy of not only funding the most impactful research in prostate cancer, but also creating new infrastructures, global knowledge networks, and research initiatives that support and accelerate prostate cancer research towards better treatment for advanced prostate cancer patients. For the past four years,.
Feb. 24, 2015 (HealthDay News) -- U.S. recommendations against the PSA test for prostate cancer might have prompted a small but measurable increase in the number of higher-risk cases diagnosed recently, according to a new study. The U.S. Preventive Services Task Force (USPSTF) in 2009 recommended that the PSA test.
Metastatic Prostate Cancer Cases Skyrocket Increase May Be Due To More Lax Screening Or More Aggressive Disease
Highest increase among men ages 55 to 69, who could benefit the most from screening and early treatment. Disease is more advanced when finally diagnosed. "Screening saves lives," urologists stress. "If I were a patient, I would want to be vigilant." Chicago -- The number of new cases of metastatic.
New study finds one in nine men with metastatic prostate cancer carry inherited mutations in DNA repair genes with important implications for treatment and for cancer risk in family members
https://www.youtube.com/embed/8pjv5M7G58U Cancer, the uncontrolled growth of cells, is caused by the acquisition of genetic mutations that allow cells to evade the normal biological laws governing when and where they can grow in the body. Mechanisms that maintain the accuracy of our genomes are critical for preventing cells from collecting mutations.
Mutations in 16 different DNA damage repair (DDR) genes have been identified as drivers of metastatic prostate cancer and other tumors, but are rare in the general population Approximately 12% of men with metastatic prostate cancer harbor inherited (germline) DDR mutations that likely caused their disease, even if.
A NEW GENOMIC CLASSIFIER ENABLES DIAGNOSIS OF THE AGGRESSIVE NEUROENDOCRINE SUBCLASS OF TREATMENT-RESISTANT PROSTATE CANCER
June 24, 2015 -- Tumor cells are continuously evolving to adapt to selective pressures introduced by changing host factors and the administration of new therapies. Following treatment with second-generation anti-androgen therapies abiraterone acetate (Zytiga®) and enzalutamide (Xtandi®), prostate tumors inevitably develop resistance and progress to lethal disease. Anti-androgen therapy-resistant prostate.
SANTA MONICA, CA June 23, 2016 – The Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) Awards to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the Class of 2016 were selected from a pool of 128 applicants from 77.
New Clinical Trial Endpoint May Speed The Development Of New Therapies For Patients With Localized Prostate Cancer
At the 2016 American Society of Clinical Oncology (ASCO) Annual Conference, Dr. Christopher Sweeney presented results from ICECaP (Intermediate Clinical Endpoints in Cancer of the Prostate), a Prostate Cancer Foundation (PCF)-supported initiative, that will halve the time required to assess new therapies for aggressive prostate cancer. "We need to move.